Related references
Note: Only part of the references are listed.Ustekinumab induction concentrations are associated with clinical and biochemical outcomes at week 12 of treatment in Crohn's disease
Margaret Walshe et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2021)
Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease
Anthony Buisson et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2021)
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
Omoniyi J. Adedokun et al.
GASTROENTEROLOGY (2018)
American Gastroenterological Association Institute Guideline on the Management of Crohn's Disease After Surgical Resection
Geoffrey C. Nguyen et al.
GASTROENTEROLOGY (2017)
American Gastroenterological Association Institute Technical Review on the Management of Crohn's Disease After Surgical Resection
Miguel Regueiro et al.
GASTROENTEROLOGY (2017)
American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease
Joseph D. Feuerstein et al.
GASTROENTEROLOGY (2017)
The Association Between Drug Levels and Endoscopic Recurrence in Postoperative Patients with Crohn's Disease Treated with Tumor Necrosis Factor Inhibitors
Shmuel Fay et al.
INFLAMMATORY BOWEL DISEASES (2017)
Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease
Robert Battat et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis
Konstantinos Papamichael et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease
Giorgia Bodini et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2016)
The Danish National Registry for Biological Therapy in Inflammatory Bowel Disease
Lone Larsen et al.
CLINICAL EPIDEMIOLOGY (2016)
Adalimumab Trough Levels and Response to Biological Treatment in Patients With Inflammatory Bowel Disease: A Useful Cutoff in Clinical Practice
Giorgia Bodini et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Niels Vande Casteele et al.
GASTROENTEROLOGY (2015)
Crohn's disease management after intestinal resection: a randomised trial
Peter De Cruz et al.
LANCET (2015)
Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab
Giorgia Bodini et al.
DIGESTIVE AND LIVER DISEASE (2014)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Share Paper
